We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » DDMAC Warns Slate Pharma for Testosterone Drug Ads
DDMAC Warns Slate Pharma for Testosterone Drug Ads
April 16, 2010
The FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) has cited Slate Pharmaceuticals for marketing claims that promote unapproved
uses of its testosterone drug Testopel, omit and minimize risk information, broaden its indication and overstate its efficacy.